Myriad Genetics, Inc. is a US-based pharmaceutical company specializing in molecular diagnostics. They offer testing services to determine an individual's risk of developing various diseases, focusing on 11 types of cancer with their flagship product, MyRisk. Their other products include BRACAnalysis CDx, GeneSight, and Prequel, catering to different medical needs. In addition, they provide Precise Oncology Solutions, combining Precise Tumor with companion diagnostic tests for personalized treatment. Myriad Genetics also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies. With a medium risk rating score of 24.2, Myriad Genetics is a reliable choice for ESG conscious investors.